Pricing Log in Create free account
Saturday 17 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.71 0.86 −1.42%
Market cap
$123.7B
P/E
13.2×
Fwd P/E
11.2×
Dividend yield
4.22%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company (BMY) Debt to equity

Alert me on Debt to equity

Bristol Myers Squibb Company's debt to equity at the end of the quarter to 30 June 2026 was 1.9×, down 0.5× from fiscal 2025 (2.4×). Over the past ten years it has ranged from 0.4× (fiscal 2016) to 3.0× (fiscal 2024); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 2.4× (19.54%)
FY2024 3.0× 124.60%
FY2023 1.3× 6.75%
FY2022 1.3× 2.12%
FY2021 1.2× (7.50%)
FY2020 1.3× 47.98%
FY2019 0.9× 73.78%
FY2018 0.5× (22.60%)
FY2017 0.7× 63.77%
FY2016 0.4× (11.49%)

Quarterly newest first

Period Debt to equity Change
Jun 2026 1.9× (12.65%)
Mar 2026 2.2× (9.27%)
Dec 2025 2.4× (7.43%)
Sep 2025 2.6× (6.37%)
42 more quarters

Against its own ten years

Low 0.4× High 3.0×
Ten-year median 1.2×
Current reading's percentile 91

Debt to equity against peers

Company Debt to equity
SNY Sanofi compare 0.3×
AZN AstraZeneca PLC compare 0.6×
NVO Novo Nordisk A/S compare 0.6×
PFE Pfizer Inc. compare 0.7×
GSK GSK PLC Sponsored ADR compare 1.1×
NVS Novartis AG compare 1.1×
BMY Bristol Myers Squibb Company 1.9×
GILD Gilead Sciences, Inc. compare 2.2×
AMGN Amgen Inc. compare 4.9×
Drug Manufacturers General industry median 0.6×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on BMY